Compare Citius Pharmaceuticals Inc (CTXR) vs Hut 8 Corp (HUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Hut 8 Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Hut 8 Corp trades at $84.2 (market cap $9.82B). The key difference: Hut 8 Corp is far larger — about 721× Citius Pharmaceuticals Inc's market cap, and Hut 8 Corp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Hut 8 Corp for 11 Days on average.
| CTXR | HUT | |
|---|---|---|
Market Cap | $13.62M | $9.82B |
Volume | 132,438 | 10,272,678 |
Sector | Health | Financials |
52-Week High | $1.82 | $133.02 |
52-Week Low | $0.48 | $33.76 |
Typical Hold Time | 17 Days | 11 Days |
Enterprise Value | $3.79M | $17.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Hut 8 Corp. (HUT) trades at $81.20, down 9.07% amid a bearish technical signal. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, with negative cash flow from operations. Recent news highlights a $1.07 billion credit facility and strong analyst buy ratings, with a consensus price target of $162.69 suggesting significant upside potential.
The outlook is mixed: robust analyst support and AI infrastructure growth opportunities contrast with persistent losses and high valuation ratios. Key risks include execution on profitability and sensitivity to sector sentiment. The stock's near-term direction hinges on earnings improvement and contract execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
